10 results about "Oleanolic acid" patented technology

Disclosed herein are oral care compositions, and preferably, oral care compositions providing reduced gingival bleeding, as well as methods for producing such oral care compositions. According to some aspects, there is provided a substrate having a stannous source; a nitrate source; a source of phosphate radicals; a surfactant system, the surfactant system comprising a sulfate based anionic surfactant; oleanolic acid; and eugenol, and an oral care composition.

The invention belongs to the technical field of medicines, and particularly relates to an experimental method for treating liver cancer by using oleanolic acid. Comprising an in-vitro experiment method and an in-vivo experiment method. The in-vitro experiment method comprises the following steps: S1, cell culture; s2, cell proliferation and migration; s3, detecting cell apoptosis and a cell cycle; s4, performing immunoblotting; s5, carrying out real-time quantitative PCR; the in-vivo experiment method comprises the following steps: step 1, performing chick embryo chorioallantoic model experiment; and 2, carrying out tumor-bearing experiment, treatment and tissue sampling on the mouse. The application of the oleanolic acid in liver cancer treatment is systematically researched for the first time, it is found that the oleanolic acid has the remarkable effects of inhibiting proliferation, inducing apoptosis, resisting angiogenesis and the like on liver tumors through the synergistic effect of multiple mechanisms, the remarkable curative effect on cancer mice is achieved, and a new medicine choice is provided for liver cancer treatment.

The application belongs to the field of new adjuvants and new dosage forms of pharmaceutical preparations, and particularly relates to a type I and type II immunogenic cell death inducer ion pairing engineered nanoassemblies as well as construction and application thereof. The nanoassemblies are composed of type I ICD inducers, type II ICD inducers, hydrophobic auxiliary counterions and amphiphilic lipid ion pairing. The type I ICD inducer is selected from mitoxantrone, doxorubicin, oxaliplatin or cyclophosphamide; the type II ICD inducer is selected from hypericin; and the hydrophobic auxiliary counterion is selected from cholesteryl sodium sulfate, cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, glycolcholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid lysine derivative, oleanolic acid and ursolic acid. The type I and type II ICD inducers are combined in the application, and have a synergistic tumor treatment effect.

The present application relates to the field of cosmetics, especially to an anti-aging essence and a preparation device, which is composed of A phase, B phase, C phase and D phase, and the components of each phase are as follows according to weight percentage: A phase: deionized water 16.15%, rose hydrolat 18.00%, propylene glycol 5.00%, glycerol 4.00%, xanthan gum 0.15%, carbomer 940 0.10%, panthenol (vitamin B5) 2.00%, boswelia (30% aqueous solution) 10.00%, ikedoin 2.00%, nicotinamide 2.00%, sodium hyaluronate compound 0.50%; B phase: polyglyceryl-6 distearate 1.20%, squalane 3.00%, isononyl isononanoate 2.00%, octyldodecanol 5.00%, rosehip oil 0.50%, argan oil 0.50%, ceramide compound powder 0.50%, cholesterol 0.30%, free fatty acid (C18-C22) 0.20%, Transcutol P 4.00%, oleanolic acid (ligustrum lucidum extract) 0.50%, plant extract compound liquid 5.00%, ergothioneine 0.30%. The advantages are that the active ingredient utilization rate is improved, the efficacy is comprehensive and the synergistic effect is strong, and the preparation device can make the mixing of each component more uniform, greatly improving the mixing efficiency.

This invention provides a CYP716 gene, protein, and applications for catalyzing the oxidation of β-amyrin at the C22α and C28 positions, belonging to the field of biotechnology. The CYP716 gene includes either CYP716BX1 (nucleotide sequence as shown in SEQ ID No. 1) or CYP716BX2 (nucleotide sequence as shown in SEQ ID No. 2). Studies have shown that CYP716BX1 and CYP716BX2 are isoenzymes, both capable of catalyzing the oxidation of β-amyrin at the C22α and C28 positions to 22α-hydroxy-kapogonadiol or 22α-hydroxy-oleanolic acid, and also capable of catalyzing the oxidation of 21β-hydroxy-β-amyrin at the C22α and C28 positions to 21β,22α-dihydroxy-kapogonadiol. This invention can provide key gene elements for the synthetic biology research of cyrimyl alcohol-type triterpenoids.

The invention provides a conyza blinii extract (tablet) fingerprint spectrum detection method, which comprises: A) taking a test sample raw material, and pre-treating to obtain a liquid to be detected; the pretreatment mode comprises solvent dissolution and extraction; b) measuring the liquid to be measured by adopting a high performance liquid chromatography-evaporative light scattering method to obtain an HPLC-ELSD (High Performance Liquid Chromatography-Evaporative Light Scattering Detector) fingerprint spectrum of the Conyza blinii extract (tablet); chromatographic conditions of the high performance liquid chromatography are as follows: a chromatographic column is a C18 column; a mobile phase A is an acetonitrile solution, a mobile phase B is a 0.1% formic acid aqueous solution, and gradient elution is carried out; according to the method, a high performance liquid chromatography-evaporative light scattering method is adopted, an acetonitrile-0. 1% formic acid aqueous solution is selected as a mobile phase for gradient elution, ursolic acid, oleanolic acid, beta-amyrin, alpha-amyrin and friedelin are taken as reference substances, and the conyza blinii extract (tablet) fingerprint detection method is established. The scientificity and the internal quality of the conyza blinii extract (tablet) are integrally evaluated.

A COMPOSITION FOR TREATING KERATIN MATERIAL AND METHODS THEREOF The present disclosure provides a composition (A) comprising: a. oleanolic acid, its salts, solvates, or their mixtures thereof; b. ursolic acid, its salts, solvates, or their mixtures thereof; c. betulinic acid, its salts, solvates, or their mixtures thereof; and d. micromeric acid, its salts, solvates, or their mixtures thereof. The present disclosure further provides a rosemary extract and a composition (B). The present disclosure also provides a process for preparing the composition (A), the extract and methods thereof.

The invention belongs to the technical field of traditional Chinese medicine detection, and particularly relates to a method for determining the contents of multiple components in oldenlandia diffusa, which adopts a high performance liquid chromatography to determine the contents of quercetin, oleanolic acid and ursolic acid in the oldenlandia diffusa. The multi-component content determination method established by the invention has the advantages of good linear range, high specificity, high accuracy, high precision, high repeatability, stability and feasibility, and can be applied to quality detection of oldenlandia diffusa.

The present disclosure addresses the problem of providing a novel autophagy inducer.　The present disclosure pertains to an autophagy inducer containing a triterpene compound, and the like. In particular, the autophagy-inducing action of cells is effectively promoted by containing an oleanane-type triterpene having a five-ring structure, oleanolic acid, an olive leaf extract, a Ligustrum lucidum extract, and the like. Said autophagy inducer can be formulated as a solid composition, a food and drink composition, a cosmetic, or a medicine, and an excipient can also be used in combination.